SUPERNUS PHARMACEUTICALS, INC. (SUPN) — SEC Financial Statements & Analysis

SUPERNUS PHARMACEUTICALS, INC. (SUPN) is a pharmaceutical preparations company, incorporated in DE. SUPERNUS PHARMACEUTICALS, INC. trades on Nasdaq as: SUPN. SUPERNUS PHARMACEUTICALS, INC. (SUPN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03. Based on that filing, SUPERNUS PHARMACEUTICALS, INC. carries a market cap of $2.70B, a P/E ratio of -24.58x, a P/B ratio of 2.62x, a P/S ratio of 3.25x, an enterprise value of $2.52B, and an EV/EBITDA multiple of -87.60x. On profitability, it posts a gross margin of 88.07%, an operating margin of -15.71%, a net margin of -13.23%, a Return on Equity (ROE) of -10.49%, a Return on Assets (ROA) of -7.82%, and a Return on Invested Capital (ROIC) of -12.91%. Per share, it reports EPS of $-1.89, diluted EPS of $-1.89, free cash flow per share of $0.32, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 24.85% year-over-year, net income growth of -270.37% year-over-year, and EPS growth of -264.37% year-over-year. On the balance sheet, it maintains a current ratio of 2.08x, a quick ratio of 1.92x, working capital of $376.12M, a debt-to-equity ratio of 0.38x, a debt ratio of 0.28, an interest coverage ratio of -56.36x, free cash flow of $18.79M (TTM), and net debt of $-181.40M. Figures sourced from SEC EDGAR.

Market Cap

$2.70B

P/E TTM

-24.58x

EPS TTM

$-1.89

P/B TTM

2.62x

ROE TTM

-10.49%

ROA TTM

-7.82%

Debt To Equity

0.38x

Free Cash Flow TTM

$18.79M

Net Revenue TTM Growth 1Y

24.85%

Data as of 2026-06-30 · Source: SEC EDGAR